ASCO 2020：11项中国研究入选口头通报，17项Poster通报

受全球新冠非典型肺炎严重影响，原定于5月底29日~6月底2日在芝加哥举行的美国针灸学亦会（ASCO）年亦会今年将首次以线上形式举办，这是目前最大规模的线上盛宴。从前，全亦会的简述题目公布，共103个sessions，东亚总计11项研究课题入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

过氧化替尼或莱切替尼加卡培他中洲使用HER2+心肌梗死发挥作用癌症（PHOEBE）：一项III期随机试验性。

大舞台：心肌梗死发挥作用癌症

译者：附属诊所诊所徐兵河讲师、马飞讲师，复旦大学附属诊所胡夕春讲师等

简述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴性发挥作用癌症标准化疗程后卡培他中洲保持节拍化疗的III期试验性（SYSUCC-001）。

大舞台：发挥作用癌症—暂时性/周边/借助于疗程

译者：厦门大学公共卫生中所心地带王树森讲师等

简述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

依靠心肌梗死脑的遗传基因特征来预测消化道中所循环DNA验证的概率: 新工具对付据说击倒

大舞台：新工具解决据说难题

译者：徐美芹 徐戈尔韦等

简述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为后期胃线粒体癌症的前沿疗程：一项解禁ID、随机、多中所心地带II/III期试验性。

大舞台：上皮线粒体癌症—肺冠状动脉、发挥作用和水火

译者：浙江大学华西诊所毕锋讲师、东亚老百姓解放军南昌诊所秦叔逵讲师等

简述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

东亚后期胃癌症高血压阿帕替尼防区疗程：一项随机、安慰剂对照、双盲III期研究课题

大舞台：上皮线粒体癌症—肺冠状动脉、发挥作用和水火

译者：东亚老百姓解放军南昌诊所秦叔逵讲师、浙江大学华西诊所徐秋讲师等

简述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后期开刀性卵巢癌症二次线粒体减灭术的一项随机III期试验性：SOC1 / SGOG-OV2。

讲座：医学癌症症

译者：复旦大学附属中所山诊所臧荣余讲师等

简述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈癌症根治性阴道切除术后借助于疗程中所的序贯放化疗对比单独放疗或不间断放化疗（STARS研究课题）：一项随机、对照、解禁ID的III期试验性。

全亦会：医学癌症症

译者：厦门大学公共卫生中所心地带黄鹤讲师、刘继红讲师等

简述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：借助于吉非替尼对比化疗使用可切除的EGFR突变的N1-N2期NSCLC-随机III期针灸性的最终总体猎食归纳。

讲座：肺炎症—非小线粒体暂时性-周边/小线粒体/其他腹部

译者：珠海市老百姓诊所吴一龙讲师等

简述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变寡集中于非小线粒体肺炎症高血压前沿嘧啶丝氨酸抑制剂合组或不合组积极前线暂时性放疗：III期解禁ID针灸随机试验性（SINDAS）的中所期结果（NCT02893332）。

讲座：肺炎症-非小线粒体集中于

译者：四川省老百姓诊所曾铭讲师等

简述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对某类死亡-1（PD-1）的人源化IgG4基因工程合组阿昔替尼使用心肌梗死上皮线粒体癌症高血压的Ib期研究课题的总猎食期和生物标志物归纳。

讲座：癌症/白内障症

译者：北京大学诊所郭军、盛锡楠讲师等

简述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的有效性和结果：通用CAR-T线粒体首次体液试验性疗程开刀/难治性T线粒体急性淋巴线粒体脑癌（r/r T-ALL）的有效性和。全亦会：应用开发中所的疗程应用-免疫疗程。译者：王志欣等简述：3013名片：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利霉素在后期冠状动脉鳞状线粒体癌症高血压中所的应用领域：一项随机的解禁IDII期试验性（ORIENT-2）。全亦会：上皮线粒体癌症-肺冠状动脉癌症、发挥作用癌症和水火道癌症译者：徐建明讲师等简述：4511名片：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T线粒体对滋养基因突变的根除性疗程全亦会：中所枢神经系统译者：代红久、孙斌、杨东、徐晖、陈晶晶、魏佳、杨旭东简述：2522名片。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后期错配修复局限性高血压中所的应用领域全亦会：应用开发中所的疗程学-免疫疗程译者：沈琳讲师等简述：3021名片。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART疗程开刀/难治性ACUTE淋巴线粒体脑癌/淋巴瘤的首例体液针灸性全亦会: 应用开发性疗程学-免疫疗程译者简介：张明志，张亮等简述：3026名片: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 利是替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度酮（T）合组应使用后期实体瘤高血压的Ib期研究课题全亦会：发展性疗程学便是分子可小分子可抗生素和生物学译者：龚继芳，沈琳讲师等简述：3523名片：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin合组吲哚和nedaplatin疗程开刀性或心肌梗死冠状动脉鳞状线粒体癌症（ESCC）高血压的II期研究课题。全亦会：上皮线粒体癌症-肺冠状动脉、发挥作用和水火道癌症的研究课题译者：王志极强，徐玉红，王德申，王凤华，任超，谭琼 王志极强、徐玉红、王德深、王凤华、任超、谭琼简述：4522名片：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全亦会：上皮线粒体癌症-肺冠状动脉癌症、发挥作用癌症和水火管癌症的防区疗程译者：宋艳等简述：4524名片：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种分泌物外体环状RNA分类器使用初始组织学时验证高等级癌症的分泌物外体环状RNA分类器：一项多中所心地带的回顾性研究课题全亦会：泌尿生殖系统癌症症便是便是癌症、乳癌症和癌症译者简介：Liaoyuan Li等简述：5522名片。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 暂时性后期宫颈癌症并发化疗后的借助于化疗全亦会: 医学癌症症译者简介： 徐珉珉等简述：6031名片：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗程甲状腺滋养性癌症的相关性：基于ALTER01031试验性的归纳。亦会讲：头颈部译者：天津市诊所娴熟讲师简述：6526名片。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄组对安洛替尼疗程后高血压故事情节的严重影响: ALTER01031的亚组归纳全亦会：头颈部译者：天津市诊所娴熟讲师简述：6527名片。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA归纳预测I-IIIA期非小线粒体肺炎症（NSCLC）高血压术后开刀: GASTO1035和GASTO1018的结果全亦会：肺炎症-非小线粒体暂时性-周边性/小线粒体/小线粒体/其他胸科癌症症译者：Si-Yu Wang等简述：9023名片：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小线粒体肺炎症（NSCLC）中所EGFR嘧啶丝氨酸抑制剂的新型病毒性前提全亦会:肺炎症-非小线粒体心肌梗死肺炎症译者简介：杨昕，金结缘，满宇，欧真假，华宝，薛武，杨少，范敏 杨昕、金结缘、满宇、欧真假、华宝、薛武、杨绍、范敏简述：9528名片：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验性中所后期癌症总猎食的替代终点全亦会：癌症/白内障症译者：聂润聪，袁书极强，徐元芳，陈英波，周志伟 聂润聪、袁书极强、徐元芳、陈英波、周志伟简述：10030名片：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗程开刀或心肌梗死继发性恶性骨高血压的II期研究课题全亦会： 肉瘤译者：唐丽娜，牛晓辉，朱德，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶简述：11525名片。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 下一步评价安罗替尼在后期肉瘤高血压多线疗程中所的有效性和。全亦会：肉瘤译者：姚伟涛，来由极强，张瑞，王志，杜新辉，田志浩，牛晓颖 姚伟涛、来由极强、张瑞、王鑫、杜鑫辉、田志超、牛晓英简述：11526名片：414